independent safety monitoring board clears drug to continue phase III trials (2/10); recruitment of additional patients expected to start 1H2010, with top-line results in 2011; announcement of expansion of phase III trial, which will start enrollment 3Q10, with completion in 2012
Brand N/A Generic isavuconazole
Company name Basilea, Astellas Product type Non-speciality
Therapeutic category Antiinfectives Key uses invasive Aspergillus infection
Other Uses N/A Drug Class antifungal
Dosage From oral Expected Approval 2012+
FDA Filing N/A Last Update date June 29,2010
Link to news article
Link to clinicaltrials.gov